Ranibizumab Plus Indomethacin

• Status: Completed
• Trial end date: 2017-07-25
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate whether indomethacin eyedrops plus intravitreal ranibizumab (IVR) provides additional benefit over IVR monotherapy for treatment of choroidal neovascularization (CNV) in age-related macular degeneration.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Università degli Studi di Brescia
• Treatments: Indomethacin; Ranibizumab

Criteria

Inclusion Criteria:

• provision of written informed consent and compliance with study assessments for the full duration of the study

• age > 40 years

• presence of treatment-naïve neovascular AMD.

Exclusion Criteria:

• any previous intravitreal treatment

• previous laser treatment in the study eye

• myopia > 7 diopters in the study eye

• concurrent eye disease in the study eye that could compromise visual acuity (e.g., diabetic retinopathy and advanced glaucoma)

• concurrent corneal epithelial disruption or any condition that would affect the ability of the cornea to heal

• known sensitivity to any component of the formulations being investigated.